Will This Spinoff's Drug Save Shareholders?

Abbott Laboratories (NYSE: ABT  ) is in the midst of some dramatic new plans. The company will soon spin off its branded pharmaceuticals business into a new entity called AbbVie. The original Abbott Laboratories will still maintain a solid mix of health care businesses. But the new spinoff has many more dynamic questions around it, since it will be heavily reliant on Abbott's powerhouse autoimmune drug, Humira, which is quickly becoming the world's best seller. In this video, Motley Fool health care analyst Brenton Flynn outlines AbbVie's situation in more detail and points out one area that could hold the key to AbbVie's future after Humira loses patent protection.

The impending spinoff of Abbott's branded-drug business is a confusing event to understand, with many investors left wondering what to do with these two stocks once they're separated. To help investors better understand the upcoming event, the Fool has created a brand new premium report outlining both Abbott Labs and its spinoff, AbbVie. Inside, we outline all of the must-know opportunities and risks facing both companies, so make sure to claim this 2-for-1 report by clicking here now


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2117482, ~/Articles/ArticleHandler.aspx, 7/24/2014 7:03:51 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement